• Hims & Hers Health (NYSE:HIMS) has entered a partnership with Novo Nordisk to offer branded Ozempic and Wegovy on the Hims platform.
• The agreement resolves their legal dispute related to compounded GLP 1 medications.
• Hims plans to stop promoting compounded alternatives while providing US patients access to FDA approved obesity treatments from Novo Nordisk.

Hims & Hers Health runs a direct to consumer telehealth and subscription platform that connects patients with clinicians and prescription treatments across categories such as hair loss, mental health and sexual health. Weight management has become a core area of interest in telehealth, as GLP 1 drugs shift from a niche therapy to a mainstream talking point with consumers.

This new tie up with Novo Nordisk may be relevant when considering NYSE:HIMS in the broader US digital health and obesity treatment space. It reduces legal friction around compounded products and positions Hims as a branded channel partner, which may affect future competition, pricing dynamics and patient acquisition strategies in weight loss telehealth.

Stay updated on the most important news stories for Hims & Hers Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Hims & Hers Health.

This agreement puts Hims & Hers at the center of the fast growing GLP 1 obesity treatment market without the legal and reputational overhang of compounded “copycat” drugs. Instead of trying to undercut Novo Nordisk with cheaper compounded semaglutide, Hims now acts as a branded distribution channel, offering Ozempic and Wegovy at Novo’s self pay prices. That shift may be less lucrative on a per prescription basis than compounded products, but it lines Hims up alongside larger telehealth peers such as Ro and WeightWatchers' telehealth offering, and could support patient trust, regulator comfort, and long term relationships with big pharma. For investors, the key questions are how much this expands Hims’ addressable customer base, what it does to unit economics in weight loss, and whether GLP 1 demand can be converted into cross selling into other verticals like mental health and hormonal care.

How This Fits Into The Hims & Hers Health Narrative

• The partnership supports the narrative around GLP 1s as a growth pillar, using high demand for obesity drugs as an on ramp to broader telehealth adoption, which aligns with expectations for strong recurring revenue from daily health programs.
• Relying on branded GLP 1s at manufacturer set prices could pressure margins in weight loss and challenge assumptions that new categories naturally support higher profitability over time.
• The narrative already highlights diversification into hormonal health, diagnostics, and international markets, but this renewed pharma partnership and its legal clean up in GLP 1s may not be fully reflected in earlier storylines about regulatory and pricing risk.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Hims & Hers Health to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Hims is moving from higher margin compounded GLP 1 offerings to fixed price branded drugs, which could weigh on profit margins if volumes or cross selling do not offset the change.
• ⚠️ GLP 1 exposure keeps regulatory and supply risks front and center, especially with past scrutiny of compounded products and ongoing attention from the FDA and the SEC.
• 🎁 The deal removes a patent lawsuit and positions Hims as a vetted partner for a leading GLP 1 producer, which may help with brand perception and future pharma collaborations.
• 🎁 Access to Ozempic and Wegovy through a direct to consumer platform could support subscriber growth and give Hims more opportunities to connect GLP 1 users to other services on its platform.

What To Watch Going Forward

From here, it is worth tracking how quickly branded Ozempic and Wegovy prescriptions ramp on the Hims platform, and whether those patients start using other services such as mental health or hormonal health programs. Pay attention to any commentary from Hims on GLP 1 related gross margins, marketing spend needed to attract and retain weight loss customers, and the balance between GLP 1 revenue and newer categories like diagnostics and menopause care. It is also important to watch for any further regulatory communication on compounded GLP 1s, plus how competitors such as Ro, WeightWatchers' telehealth arm, and traditional providers respond to broader GLP 1 access online.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Hims & Hers Health, head to the community page for Hims & Hers Health to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.